Proxy Touts Growing Sales, Not Worried About HID Threat

By Brian Rhodes, Published Mar 04, 2021, 09:40am EST (Info+)

HID made waves in December 2020 that put rival startup Proxy on notice about being 'parasitic'. 3 months later, Proxy has effectively shrugged it off, touting growing sales to IPVM.

IPVM Image

In this note, we examine Proxy's response and where this places HID.

Proxy *********

***** ********* ** ****'* ******* *** comment ** *** ***'* ******* ******** Proxy, ******:

*** ***** ** **** ******* **** continued ** *** ********* ****** (***% m/m).

*** ********* ***'* *** **** ** parasites, ****** ** ******** ******* **** provide **** ****** ** *** ******. Our ****** ******* ******** *** ****** the ****, **** *** ** ** partnering **** ****-**-***** ****** ****** *** their *** **** ** **** ** a *********** **************.

******, *****'* ********* ********* **** ***'* 'parasite ****** ********' *** * ******* negative ****** ** ***** ** *** device ** ******* ******* *****.

HID: "********* ******* **" *** *******

*** ***** **** ***** ******* *** changed ** ****** ** ***** ******** advisory, **** **** ********* **** ************ of *** *******:

** **** ** ******* ** *** policy *** ** *** ****. **** of *** ********* ******* *** ** thank ** *** ************* ** *** relationship **** ***** *******.

Issue **********

*** ******** ***** ***** ****** ******* ************ '*********' *********** ************ ******* ********** ********* ******* ******** *** ********** *** tech *******.

** ********, ************ ** ******** *** *** *** started ******** '* **** ***** ****** to ******* *** ********* ********* *** operational *** ******'.

Outlook *** ********

***** *** ** *** *********** ****** reader ******** ****** ****** ************, **** ** * *********** ********* for ****. *** **** * ********, public **** **** *** ****** ***, so ***, ***'* ******* *********** *** standing ***** ******, ******** ***'* ******.

*********'* $** ******* ** ********** ***** ******** ****, ** ****** Proxy ** ****** ***** *********** ********* (or ********** ********* ** ***'* ***** of ****) ** *** *******. **** may ****** ** *********** *********** ******* where *** ***** ***** *** ****** further ** ****** **** ********** ****** to ******** **** ***** ** **** litigate ******* *****.

****/****

Comments (0)

Login to read this IPVM report.
Why do I need to log in?
IPVM conducts reporting, tutorials and software funded by subscriber's payments enabling us to offer the most independent, accurate and in-depth information.
Loading Related Reports